Optimal Dose and Type of beta-blockers in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jiesuck | - |
dc.contributor.author | Han, Jung-Kyu | - |
dc.contributor.author | Kang, Jeehoon | - |
dc.contributor.author | Chae, In-Ho | - |
dc.contributor.author | Lee, Sung Yun | - |
dc.contributor.author | Choi, Young Jin | - |
dc.contributor.author | Rhew, Jay Young | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Shin, Eun-Seok | - |
dc.contributor.author | Woo, Seong-Ill | - |
dc.contributor.author | Lee, Han Cheol | - |
dc.contributor.author | Chun, Kook-Jin | - |
dc.contributor.author | Kim, Doo-Il | - |
dc.contributor.author | Jeong, Jin-Ok | - |
dc.contributor.author | Bae, Jang-Whan | - |
dc.contributor.author | Yang, Han-Mo | - |
dc.contributor.author | Park, Kyung Woo | - |
dc.contributor.author | Kang, Hyun-Jae | - |
dc.contributor.author | Koo, Bon-Kwon | - |
dc.contributor.author | Kim, Hyo-Soo | - |
dc.date.accessioned | 2021-12-08T09:42:02Z | - |
dc.date.available | 2021-12-08T09:42:02Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2020-12-15 | - |
dc.identifier.issn | 0002-9149 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/130298 | - |
dc.description.abstract | The clinical benefit of beta-blockers in modern reperfusion era is not well determined. We investigated the impact of beta-blockers in acute coronary syndrome (ACS) after percutaneous coronary intervention. From the Grand-DES registry, a patient-level pooled registry consisting of 5 Korean multicenter prospective drug-eluting stent registries, a total of 6,690 ACS patients were included. Prescription records of dose and type of beta-blockers were investigated trimonthly from discharge. Patients were categorized by the mean value of doses during the follow-up (>= 50% [high-dose], >= 25% to < 50% [medium-dose], and < 25% [lowdose] of the full dose that was used in each randomized clinical trial) and vasodilating property of beta-blockers. Three-year cumulative risk of all-cause death, cardiac death, and myocardial infarction were assessed. Patients receiving beta-blockers were associated with a lower risk of all-cause and cardiac death compared with those not receiving beta-blockers (adjusted hazard ratio [aHR] 0.29, 95% confidence interval [CI] 0.24 to 0.35 for all-cause death; aHR 0.27, 95% CI 0.21 to 0.34 for cardiac death). Medium-dose beta-blocker group was associated with a lower risk of cardiac death compared with high- and low-dose beta-blocker groups (aHR 0.49, 95% CI 0.25 to 0.96, for high-dose; aHR 0.46, 95% CI 0.29 to 0.74, for low-dose). Patients receiving vasodilating beta-blockers were associated with a lower risk of cardiac death compared with those receiving conventional beta-blockers (aHR 0.58, 95% CI 0.40 to 0.84). In conclusion, beta-blocker therapy was associated with better clinical outcomes in patients with ACS, especially with medium-dose and vasodilating beta-blockers. (c) 2020 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC | - |
dc.subject | ACUTE MYOCARDIAL-INFARCTION | - |
dc.subject | CLINICAL-OUTCOMES | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | THERAPY | - |
dc.subject | PROPRANOLOL | - |
dc.subject | METOPROLOL | - |
dc.subject | DISCHARGE | - |
dc.subject | MORTALITY | - |
dc.subject | BLOCKADE | - |
dc.subject | ANGINA | - |
dc.title | Optimal Dose and Type of beta-blockers in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rha, Seung-Woon | - |
dc.identifier.doi | 10.1016/j.amjcard.2020.09.044 | - |
dc.identifier.scopusid | 2-s2.0-85093669428 | - |
dc.identifier.wosid | 000594528000003 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CARDIOLOGY, v.137, pp.12 - 19 | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CARDIOLOGY | - |
dc.citation.title | AMERICAN JOURNAL OF CARDIOLOGY | - |
dc.citation.volume | 137 | - |
dc.citation.startPage | 12 | - |
dc.citation.endPage | 19 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | ACUTE MYOCARDIAL-INFARCTION | - |
dc.subject.keywordPlus | CLINICAL-OUTCOMES | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | PROPRANOLOL | - |
dc.subject.keywordPlus | METOPROLOL | - |
dc.subject.keywordPlus | DISCHARGE | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | BLOCKADE | - |
dc.subject.keywordPlus | ANGINA | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.